Disc Medicine director receives 6,212 stock options
Disc Medicine, Inc. director Kevin Bitterman received a grant of stock options covering 6,212 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Disc Medicine, Inc. director Kevin Bitterman received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.
The options vest on the earlier of the company’s 2027 annual stockholders’ meeting or the one-year anniversary of the grant date, subject to his continued service. Footnotes state that proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Bitterman disclaims ownership of the securities except for any pecuniary interest.
Insider Trade Summary
Grant/Award: 6,212 shares
Grant/Award
1 txn
Insider
Bitterman Kevin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,212 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,212 contracts (Direct)
Footnotes (2)
- F1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
- F2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Key Figures
Option grant size: 6,212 options
Exercise price: $70.79 per share
Expiration date: June 17, 2036
+1 more
4 metrics
Option grant size
6,212 options
Number of common shares underlying the stock option grant
Exercise price
$70.79 per share
Conversion or exercise price of the stock options
Expiration date
June 17, 2036
Option expiration date for the grant
Post-transaction derivative holdings
6,212 options
Total derivative securities following the reported grant
Key Terms
Stock Option (Right to Buy), exercise price, Section 16, pecuniary interest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 70.7900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Section 16 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
annual meeting financial
"the date of the Company's 2027 annual meeting of its stockholders"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Disc Medicine (IRON) report for Kevin Bitterman?
Disc Medicine reported a stock option grant to director Kevin Bitterman for 6,212 underlying common shares. The options are a compensation-related award rather than an open-market trade and give the right to buy shares at a set exercise price.
What are the key terms of Kevin Bitterman’s stock options at Disc Medicine (IRON)?
The grant covers 6,212 shares of Disc Medicine common stock with an exercise price of $70.79 per share. The options expire on June 17, 2036, providing a long-term right to purchase shares at that fixed price.
When do Kevin Bitterman’s Disc Medicine (IRON) options vest?
The options vest on the first to occur of the company’s 2027 annual stockholders’ meeting or one year after the grant date. Vesting is conditioned on Bitterman’s continued service with the company through the applicable vesting date.
Is Kevin Bitterman’s Disc Medicine (IRON) Form 4 transaction a stock purchase or sale?
No, the Form 4 reports a grant of stock options, classified as an acquisition of a derivative security. It is a compensation award, not an open-market stock purchase or sale, and does not itself involve trading Disc Medicine common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates